These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3720216)

  • 21. Outpatient management of warfarin therapy: comparison of computer-predicted dosage adjustment to skilled professional care.
    White RH; Mungall D
    Ther Drug Monit; 1991 Jan; 13(1):46-50. PubMed ID: 2057991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased serum phenytoin concentration following influenza vaccination.
    Levine M; Jones MW; Gribble M
    Clin Pharm; 1984; 3(5):505-9. PubMed ID: 6488730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
    J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of drug interactions on outcomes of patients receiving warfarin or theophylline.
    Jankel CA; McMillan JA; Martin BC
    Am J Hosp Pharm; 1994 Mar; 51(5):661-6. PubMed ID: 8203385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Warfarin does not interfere with lupus anticoagulant detection by dilute Russell's viper venom time.
    Olteanu H; Downes KA; Patel J; Praprotnik D; Sarode R
    Clin Lab; 2009; 55(3-4):138-42. PubMed ID: 19462936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of influenza vaccine on warfarin anticoagulation.
    Kramer P; Tsuru M; Cook CE; McClain CJ; Holtzman JL
    Clin Pharmacol Ther; 1984 Mar; 35(3):416-8. PubMed ID: 6697649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How to monitor the dosage of warfarin.
    Bussey HI
    Heart Dis Stroke; 1993; 2(5):388-92. PubMed ID: 8137040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influenza vaccination and warfarin anticoagulation: a comparison of subcutaneous and intramuscular routes of administration in elderly men.
    Delafuente JC; Davis JA; Meuleman JR; Jones RA
    Pharmacotherapy; 1998; 18(3):631-6. PubMed ID: 9620115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial.
    Dentali F; Douketis JD; Woods K; Thabane L; Foster G; Holbrook A; Crowther M
    Ann Pharmacother; 2006; 40(7-8):1241-7. PubMed ID: 16804099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study.
    Lee HL; Kan CD; Yang YJ
    Clin Ther; 2005 Mar; 27(3):309-19. PubMed ID: 15878384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of vinpocetine on warfarin-induced inhibition of coagulation.
    Hitzenberger G; Sommer W; Grandt R
    Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):323-8. PubMed ID: 2272713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
    Schwartz JI; Bugianesi KJ; Ebel DL; De Smet M; Haesen R; Larson PJ; Ko A; Verbesselt R; Hunt TL; Lins R; Lens S; Porras AG; Dieck J; Keymeulen B; Gertz BJ
    Clin Pharmacol Ther; 2000 Dec; 68(6):626-36. PubMed ID: 11180023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
    J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective evaluation of a possible interaction between warfarin and levofloxacin.
    McCall KL; Scott JC; Anderson HG
    Pharmacotherapy; 2005 Jan; 25(1):67-73. PubMed ID: 15767222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modified anticoagulant therapy factor and international normalized ratio in patients in an unstable coagulation state with respect to warfarin therapy.
    Carroll WE; Jackson RD
    Res Commun Mol Pathol Pharmacol; 1999; 105(3):262-70. PubMed ID: 10954130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity.
    Del Porto F; Laganà B; Biselli R; Donatelli I; Campitelli L; Nisini R; Cardelli P; Rossi F; D'Amelio R
    Vaccine; 2006 Apr; 24(16):3217-23. PubMed ID: 16466833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy.
    Anderson DR; Harrison L; Hirsh J
    Arch Intern Med; 1993 Jun; 153(12):1441-7. PubMed ID: 8512435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cranberry does not affect prothrombin time in male subjects on warfarin.
    Li Z; Seeram NP; Carpenter CL; Thames G; Minutti C; Bowerman S
    J Am Diet Assoc; 2006 Dec; 106(12):2057-61. PubMed ID: 17126638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin.
    Wieloch M; Hillarp A; Strandberg K; Nilsson C; Svensson PJ
    Thromb Res; 2009 Jul; 124(3):344-8. PubMed ID: 19423152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.